In the VERITAC‐2 pivotal Phase III clinical trial (NCT05654623), the study enrolled 624 patients with ER+/HER2− advanced breast cancer previously treated with CDK4/6 inhibitors and endocrine therapy, with primary endpoint of PFS [358]. This evidence concerns the gene ESR1 and breast carcinoma.